The lack of information about the pathophysiological role of TGFα in kidney cancer, together with the conflicting results reported on EGFR, motivated us to further evaluate the biological relevance of targeting the EGFR-TGFα system in this pathology. This evidence concerns the gene EGFR and kidney cancer.